PinnyPeptide

AOD-9604 vs Semaglutide

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

AOD-9604

Weight Management

Fat-metabolizing fragment of human growth hormone without growth-promoting effects.

Peptide B

Semaglutide

Weight Management

GLP-1 receptor agonist revolutionizing the treatment of obesity and type 2 diabetes.

Typical vial

5 mg

Typical dose

250-500 mcg

Half-life

~30-60 minutes

FDA status

Not FDA approved as a drug. Granted GRAS status as a food ad…

Typical vial

3 mg

Typical dose

250-2400 mcg

Half-life

~7 days (168 hours)

FDA status

FDA approved. Ozempic (2017) for type 2 diabetes, Rybelsus (…

AOD-9604 effects

  • Stimulates lipolysis (fat breakdown) in adipose tissue
  • Inhibits lipogenesis (new fat formation)
  • Does not affect blood glucose or insulin levels
  • Does not elevate IGF-1 or bind the GH receptor
  • May support cartilage repair (emerging research)

Semaglutide effects

  • Significant and sustained weight loss (15-17% body weight in trials)
  • Improved glycemic control and reduced HbA1c
  • Reduced appetite and food cravings through central satiety signaling
  • Cardiovascular risk reduction (20% MACE reduction in SELECT trial)
  • Slowed gastric emptying for prolonged satiety
  • Improved insulin sensitivity and beta-cell function

AOD-9604 side effects

  • Injection site irritation or redness
  • Occasional headache
  • Mild nausea (uncommon)
  • Transient lightheadedness

Semaglutide side effects

  • Nausea (most common, especially during dose titration)
  • Vomiting and diarrhea
  • Constipation
  • Abdominal pain and dyspepsia
  • Pancreatitis (rare but serious)

AOD-9604 dosing ranges

Fat loss and body composition

250-500 mcg · Once daily (SubQ) · 8-12 weeks

Semaglutide dosing ranges

Type 2 diabetes (Ozempic)

250-1000 mcg · Once weekly (SubQ) · Ongoing as prescribed

Weight management (Wegovy)

2400 mcg · Once weekly (SubQ, after 16-week titration) · Ongoing as prescribed

Full AOD-9604 guide → Full Semaglutide guide →

AOD-9604 vs Semaglutide — common questions

What is the difference between AOD-9604 and Semaglutide?

AOD-9604: Fat-metabolizing fragment of human growth hormone without growth-promoting effects. Typical dose 250-500 mcg. Semaglutide: GLP-1 receptor agonist revolutionizing the treatment of obesity and type 2 diabetes. Typical dose 250-2400 mcg. Both fall under the Weight Management category.

Can you stack AOD-9604 and Semaglutide?

Stacking AOD-9604 with Semaglutide is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, AOD-9604 or Semaglutide?

AOD-9604 is typically dosed: Once daily (SubQ) for Fat loss and body composition. Semaglutide is typically dosed: Once weekly (SubQ) for Type 2 diabetes (Ozempic); Once weekly (SubQ, after 16-week titration) for Weight management (Wegovy).

Are AOD-9604 and Semaglutide FDA approved?

AOD-9604: Not FDA approved as a drug. Granted GRAS status as a food additive in 2014. Semaglutide: FDA approved. Ozempic (2017) for type 2 diabetes, Rybelsus (2019) oral for diabetes, Wegovy (2021) for chronic weight management.

Related peptide comparisons

aod-9604 vs cjc-1295aod-9604 vs ftpp-adipotideaod-9604 vs hgh-fragment-176-191aod-9604 vs ipamorelinaod-9604 vs retatrutideftpp-adipotide vs semaglutide

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free